Halozyme Therapeutics Inc (HALO)vsVertex Pharmaceuticals Inc (VRTX)
HALO
Halozyme Therapeutics Inc
$63.24
+1.93%
HEALTHCARE · Cap: $7.32B
VRTX
Vertex Pharmaceuticals Inc
$454.97
+1.42%
HEALTHCARE · Cap: $113.95B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 759% more annual revenue ($12.00B vs $1.40B). VRTX leads profitability with a 32.9% profit margin vs 22.7%. HALO trades at a lower P/E of 24.2x. HALO earns a higher WallStSmart Score of 70/100 (B).
HALO
Strong Buy70
out of 100
Grade: B
VRTX
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+33.6%
Fair Value
$119.81
Current Price
$63.24
$56.57 discount
Margin of Safety
+36.5%
Fair Value
$716.04
Current Price
$454.97
$261.07 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 56.3%
Revenue surging 51.6% year-over-year
Keeps 23 of every $100 in revenue as profit
Earnings expanding 36.2% YoY
Keeps 33 of every $100 in revenue as profit
Strong operational efficiency at 39.6%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 23 in profit
Conservative balance sheet, low leverage
Areas to Watch
ROE of 1.5% — below average capital efficiency
Trading at 154.2x book value
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : HALO
The strongest argument for HALO centers on Operating Margin, Revenue Growth, Profit Margin. Profitability is solid with margins at 22.7% and operating margin at 56.3%. Revenue growth of 51.6% demonstrates continued momentum.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 32.9% and operating margin at 39.6%.
Bear Case : HALO
The primary concerns for HALO are Return on Equity, Price/Book.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
HALO profiles as a growth stock while VRTX is a mature play — different risk/reward profiles.
HALO carries more volatility with a beta of 1.02 — expect wider price swings.
HALO is growing revenue faster at 51.6% — sustainability is the question.
VRTX generates stronger free cash flow (349M), providing more financial flexibility.
Bottom Line
HALO scores higher overall (70/100 vs 66/100), backed by strong 22.7% margins and 51.6% revenue growth. VRTX offers better value entry with a 36.5% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Halozyme Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company is headquartered in San Diego, California.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?